Earnings ·
Smith+Nephew reported first-half 2026 revenue of $3,097 million, up 4.6% reported and 2.3% underlying, with trading…
SNNUFSmith & Nephew PLC
Smith+Nephew reported first-half 2026 revenue of $3,097 million, up 4.6% reported and 2.3% underlying, with trading profit rising 8.1% to $566 million and adjusted EPS increasing 11.0% to 47.7 cents. The company announced an interim dividend increase of 4.0% to 15.6 cents per share and disclosed that $216 million of a $500 million share buyback program had been settled by early August. Full-year revenue guidance was reduced from approximately 6% to around 4%, while trading profit, free cash flow, and ROIC targets remained unchanged at roughly $1.3 billion, $800 million, and over 10%, respectively. Smith+Nephew operates in the medical technology industry, specializing in the repair, regeneration, and replacement of soft and hard tissue through its Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management divisions.